Challenges of urine-based molecular assays for the detection of urothelial cancer

Joep J. de Jong, Kim E. M. van Kessel, Monique J. Roobol, Joost L. Boormans


In the issue of Modern Pathology, April 25 2019, Eich and colleagues highlight the relevance of a urine assay called ‘UroSEEK’ as a non-invasive approach for the detection of primary or recurrent urothelial carcinoma of the bladder (UCB). The UROSEEK assay consists of three components; TERTSeqS, UroSeqS, and FastSeqS, which cover molecular alterations in 11 genes that frequently occur in UCB, in addition to aneuploidy (FastSeqS) (1).